111 related articles for article (PubMed ID: 12774002)
1. Viral kinetics in hepatitis C.
Lutchman G; Hoofnagle JH
Hepatology; 2003 Jun; 37(6):1257-9. PubMed ID: 12774002
[No Abstract] [Full Text] [Related]
2. [Current and future applications of viral clearance kinetics in the treatment of hepatitis C].
Buti M
Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():24-9. PubMed ID: 15195531
[No Abstract] [Full Text] [Related]
3. [Recent progress in the treatment of interferon-resistant hepatitis C].
Kumada M
Nihon Naika Gakkai Zasshi; 1999 Sep; 88(9):1759-62. PubMed ID: 10581760
[No Abstract] [Full Text] [Related]
4. Diagnosis and management of hepatitis C virus-infected children.
Jhaveri R
Pediatr Infect Dis J; 2011 Nov; 30(11):983-5. PubMed ID: 21997662
[No Abstract] [Full Text] [Related]
5. Prediction of relapse following treatment for hepatitis C: is whole blood more than the sum of its parts?
Shire N; Koziel MJ
Clin Infect Dis; 2004 Dec; 39(12):1761-3. PubMed ID: 15578396
[No Abstract] [Full Text] [Related]
6. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
8. Mathematical modeling of HCV infection and treatment.
Dahari H; Shudo E; Ribeiro RM; Perelson AS
Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C co-infection review.
Raymond D
Posit Aware; 2004; 15(2):28-30, 33. PubMed ID: 15106528
[No Abstract] [Full Text] [Related]
10. Novel interferons for treatment of hepatitis C virus.
Clark V; Nelson DR
Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
[TBL] [Abstract][Full Text] [Related]
11. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
Giostra E; Kullak-Ublick GA; Keller W; Fried R; Vanlemmens C; Kraehenbuhl S; Locher S; Egger HP; Clavien PA; Hadengue A; Mentha G; Morel P; Negro F
Transpl Int; 2004 May; 17(4):169-76. PubMed ID: 15060764
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of alanine aminotransferase during hepatitis C virus treatment.
Ribeiro RM; Layden-Almer J; Powers KA; Layden TJ; Perelson AS
Hepatology; 2003 Aug; 38(2):509-17. PubMed ID: 12883496
[TBL] [Abstract][Full Text] [Related]
13. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
Shedlofsky SI
Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
[No Abstract] [Full Text] [Related]
14. Treating patients with HCV genotype 1 and low viraemia: more than meets the eye.
Craxì A; Cammà C
J Hepatol; 2006 Jan; 44(1):4-7. PubMed ID: 16293337
[No Abstract] [Full Text] [Related]
15. Novel hepatitis C drugs in current trials.
Kronenberger B; Welsch C; Forestier N; Zeuzem S
Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
[TBL] [Abstract][Full Text] [Related]
16. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase.
Colombatto P; Civitano L; Oliveri F; Coco B; Ciccorossi P; Flichman D; Campa M; Bonino F; Brunetto MR
Antivir Ther; 2003 Dec; 8(6):519-30. PubMed ID: 14760885
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of hepatitis C. Different modalities based on viral genotype].
Pariente A
Rev Prat; 2003 Jun; 53(11):1175-6. PubMed ID: 15185639
[No Abstract] [Full Text] [Related]
18. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
[No Abstract] [Full Text] [Related]
19. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic prospects in HCV treatment.
Almasio PL; Ingrassia D; Vergara B; Filosto S
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):775-9. PubMed ID: 19053890
[No Abstract] [Full Text] [Related]
[Next] [New Search]
